Penmenvy — A Second Pentavalent Meningococcal Vaccine

The FDA has licensed the pentavalent vaccine Penmenvy (GSK) for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. Penmenvy is the second pentavalent meningococcal vaccine to become available in the US; Penbraya was licensed in 2023.

Publication Details

Journal: The medical letter on drugs and therapeutics/The medical letter
Published: 2025-04-03
DOI: https://doi.org/10.58347/tml.2025.1726a
Citations: 2
Primary Topic: Bacterial Infections and Vaccines
Type: article
Field-Weighted Citation Impact: 2.37

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Penmenvy — A Second Pentavalent Meningococcal Vaccine

Apr 3, 2025

2 citations

The medical letter on drugs and therapeutics/The medical letter

Bacterial Infections and Vaccines

2.37

article

Penmenvy — A Second Pentavalent Meningococcal Vaccine

April 3, 2025article en

2 citations

Abstract

The medical letter on drugs and therapeutics/The medical letterVol. 67(1726)

Good health and well-being

Openalex Percentile: Top 13%

Bacterial Infections and Vaccines

2.37

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Penmenvy — A Second Pentavalent Meningococcal Vaccine · The medical letter on drugs and therapeutics/The medical letter (2025) | TGRS Research Map | TGRS